Signaling Pathway
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
| Discription | Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy | ||
|---|---|---|---|
| Targets |
|
| Catalog Num | A11592 |
|---|---|
| Formula | C19H14N2O2S |
| Molecular Weight | 334.39 |
| CAS Number | 865854-05-3 |
| SMILES | C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
| In vitro (25°C) | DMSO | Warmed: 7 mg/mL (20.93 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
| In vivo | 4% DMSO+corn oil | 2.3 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 29.91 mL | 149.53 mL | 299.05 mL |
| 0.5 mM | 5.98 mL | 29.91 mL | 59.81 mL |
| 1 mM | 2.99 mL | 14.95 mL | 29.91 mL |
| 5 mM | 0.6 mL | 2.99 mL | 5.98 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
